State of HPV16 integration in Lithuanian women with cervical neoplasia

• Authors: Agne Sepetiene , Zivile Gudlevicienė , Zana Bumbuliene , Grazina Drasutiene , Janina Didziapetriene
• Languages of publication: EN

Abstracts

EN

Cervical cancer morbidity and mortality in Lithuania is one of the biggest in the European Union. The main risk factor of cervical cancer is human papillomavirus (HPV). The deletion of the HPV E2 gene influences HPV DNA integration into the cell genome, as well as a rapid progression of cervical lesions. The purpose of this study is to determine HPV, its types, and HPV 16 integration in different grades of cervical intraepithelial neoplasias (CIN). 253 women with cytological lesions were involved in the study. After a histology, 31 women were diagnosed with CIN I, 35 with CIN II, and 51 with CIN III. The biggest prevalence of HPV infection was detected in women younger than 25 years old (69.7%) and in women with CIN II (90.9%). HPV 16 was detected in 67.8% of all cases, with the highest prevalence in CIN III (84.4%). A partial integration form was detected in 65.0% of HPV 16 infected women, a complete virus integration in 26.5%, and an episomal form in 8.4% of cases. Our study concludes that in all the cases confirmed using a histology, the partial virus integration form of CIN was identified the most. It was less frequently detected in CIN I cases (60.0%), but more frequently in CIN II and CIN III cases (72.8 and 69.3%, respectively).

Keywords

EN

HPV prevalence; HPV 16 integration; Cervical intraepithelial neoplasia

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2011
• Volume: 6
• Issue: 2
• Pages: 205-212

Dates

published

1 - 4 - 2011

online

17 - 2 - 2011

Contributors

author

Agne Sepetiene

author

Zivile Gudlevicienė

• Institute of Oncology, Vilnius University, Santariskiu 1, LT-08660, Vilnius, Lithuania

author

Zana Bumbuliene

author

Grazina Drasutiene

• Faculty of Medicine, Clinic of Obstetrics and Gynecology, Vilnius University, M.K. Ciurlionio 21, LT-03101, Vilnius, Lithuania

author

Janina Didziapetriene

References

• [1] Castellsague X., de Sanjose S., Aguado T., Louie K.S., Bruni L., Munoz J. et. al. HPV and cervical cancer in the World, Vaccine, 2007, 25S, C1–26
• [2] Lithuanian Cancer Registry. Institute of Oncology, Vilnius University. Preliminary data for 2009 available at http://www.vuoi.lt/l.php?tmpl
• [3] Anttila A., Ronco G. Description of the national situation of cervical cancer screening in the member states of the European Union, Eur J Cancer, 2009, 45(15), 2685–2708 http://dx.doi.org/10.1016/j.ejca.2009.07.017[Crossref]
• [4] Hoory T., Monie A., Gravitt P., Wu T.C. Molecular epidemiology of human papillomavirus. J Formos Med Assoc., 2008, 107(3), 198–217 http://dx.doi.org/10.1016/S0929-6646(08)60138-2[Crossref]
• [5] Gudleviciene Z., Ramael M., Didziapetriene J., Uleckiene S., Valuckas K.P. Human papillomavirus and p53 polymorphism in Lithuanian cervical carcinoma patients. Oncol Gynecol., 2006, 102, 530–533 http://dx.doi.org/10.1016/j.ygyno.2006.01.019
• [6] Kraus I., Molden T., Holm R., Lie A.K., Karlsen F., Kristensen G.B. et. al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33 and 45 in the majority of cervical carcinomas, J of Clin Microbiol., 2006, 44(4), 1310–1317 http://dx.doi.org/10.1128/JCM.44.4.1310-1317.2006[Crossref]
• [7] Molijn A., Kleter B., Quint W., van Doorn L.J. Molecular diagnosis of human papillomavirus (HPV) infections. J of Clin Virology, 2005, 32(1), S43–S51 http://dx.doi.org/10.1016/j.jcv.2004.12.004[Crossref]
• [8] Longworth M.S., Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelium. Microbiol Mol Biol Rev., 2004, 68(2), 362–372 http://dx.doi.org/10.1128/MMBR.68.2.362-372.2004[Crossref]
• [9] Cheung J.L.K., Keith W.K.L., Cheung T.H., Tang J.W., Chan P.K.S. Viral load, E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J of Infect Dis., 2006, 194, 1706–1712 http://dx.doi.org/10.1086/509622[Crossref]
• [10] Stanley M. Pathology and epidemiology of HPV infection in females, Gynecol Oncol., 2010, 117, S5–S10 http://dx.doi.org/10.1016/j.ygyno.2010.01.024[Crossref][WoS]
• [11] Woodman C.B.J., Collins S.I., Young L.S. The nature history of cervical HPV infection: unresolved issues, Nat Rev Cancer, 2007, 7(1), 11–22 http://dx.doi.org/10.1038/nrc2050[Crossref][WoS]
• [12] Graham D.A., Herrington C.S. HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities, J Clin Pathol: Mol Pathol., 2000, 53, 201–206 http://dx.doi.org/10.1136/mp.53.4.201[Crossref]
• [13] Kliucinskas M., Nadisauskienė R.J., Padaiga Z., Spukaitė T. Prevalence of human papillomavirus among 18–35-aged Kaunas women, Lithuanian obstetrics and gynecology, 1999, 2(1), 19–22, (in Lithuanian)
• [14] Kliucinskas M., Nadisauskiene R.J., Minkauskiene M. Prevalence and risk factors of HPV infection among high-risk rural and urban Lithuanian women. Gynecol Obstet Invest 2006;62(3):173–180 http://dx.doi.org/10.1159/000093572[Crossref]
• [15] Gudlevičienė Z., Didziapetriene J., Suziedelis K., Lapkauskaite L. Investigation of human papillomavirus, its types and variants, Medicina, 2005, 41(11), 910–915, (in Lithuanian)
• [16] Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections, J of Clin Virol., 2005, 32(1), S16–S24 http://dx.doi.org/10.1016/j.jcv.2004.12.008[Crossref]
• [17] Bosch F.X., Burchell A.N., Schiffman M., Giuliano M.R., de Sanjose S., Bruni L. et. al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia, Vaccine, 2008, 26(Suppl 10), K1–K16 http://dx.doi.org/10.1016/j.vaccine.2008.05.064[WoS][Crossref]
• [18] Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R. et. al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst., 2005, 97(14), 1072–1079 http://dx.doi.org/10.1093/jnci/dji187[Crossref]
• [19] Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities, J Natl Cancer Inst., 2005, 97(14), 1066–1071 http://dx.doi.org/10.1093/jnci/dji186[Crossref]
• [20] de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N. et. al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis., 2007, 7(7), 453–459 http://dx.doi.org/10.1016/S1473-3099(07)70158-5[Crossref][WoS]
• [21] Andersson S., Hansson B., Norman I., Gaberi V., Mints M., Hjerpe A. et. al. Expression of E6/ E7 mRNA from high-risk human papillomavirus in relation to CIN grade, viral load and p16INK4A, Int J of Oncol., 2006, 29(3), 705–711
• [22] Pett M., Coleman N. Integration of high risk human papillomavirus: a key event in cervical carcinogenesis? The J of Pathol., 2007, 212(4), 356–367 http://dx.doi.org/10.1002/path.2192[WoS][Crossref]
• [23] Tinelli A., Vergara D., Leo G., Malvasi A., Casciaro S., Leo E. et. al. Human papillomavirus genital infection in modern gynecology: genetic and genomic aspects, Eur Clin in Obst and Gynaecol., 2007, 3(1), 1–6 http://dx.doi.org/10.1007/s11296-007-0064-y[Crossref]
• [24] Arias-Pulido H., Peyton C.L., Joste N.E., Vargas H., Wheeler C.M. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer, J of Clin Microbiol., 2006, 44(5), 1755–1762 http://dx.doi.org/10.1128/JCM.44.5.1755-1762.2006[Crossref]
• [25] Huang L.W., Chao S.L., Lee B.H. Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis, J of Clin Pathol., 2008, 61, 627–631 http://dx.doi.org/10.1136/jcp.2007.052027[WoS][Crossref]
• [26] Collins S.I., Williams C.C., Wen K., Young L.S., Roberts S., Murray P.G., et. al. Disruption of the E2 Gene Is a Common and Early Event in the Natural History of Cervical Human Papillomavirus Infection: A Longitudinal Cohort Study, Cancer Res, 2009, 69:(9), 3828–3832 http://dx.doi.org/10.1158/0008-5472.CAN-08-3099[WoS][Crossref]
• [27] Kulmala S.M.A., Syrjänen S.M., Gyllensten U.B., Shabalova I.P., Petrovichev N., Tosi P. et. al. Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology, Clin Pathol., 2006, 59(5), 513–517 http://dx.doi.org/10.1136/jcp.2004.024570[Crossref]

Identifiers

DOI

10.2478/s11536-011-0004-6